Status:

UNKNOWN

Biological Markers for the Diagnosis of Central Nervous System Infective Diseases

Lead Sponsor:

Xijing Hospital

Conditions:

Infection

Eligibility:

All Genders

13+ years

Brief Summary

Bacterial meningitis is a potentially life-threatening disease that is associated with substantial neurological morbidity and mortality. Accurate diagnosis is essential to improve outcome and prevent ...

Detailed Description

To investigate the diagnosis value of procalcitonin,interleukin-6, agiotensininⅡin the cerebrospinal fluid in the central nervous system infection disease.

Eligibility Criteria

Inclusion

  • Aged 13 years or older;
  • At least two of the following clinical characteristics:headache, fever, neck stiffness, mental symptoms or consciousness impairment or seizures
  • Patients' family signed informed consent.

Exclusion

  • Contraindications to lumbar puncture
  • Patients with active malignancy

Key Trial Info

Start Date :

August 1 2014

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

July 1 2017

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT02278016

Start Date

August 1 2014

End Date

July 1 2017

Last Update

January 1 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Xijing Hospital

Xi'an, Shaanxi, China, 710032